FLT3酪氨酸激酶抑制调控PRC2并促进急性髓系白血病分化
研究通过蛋白组学筛选发现FLT3抑制剂下调EZH2蛋白表达及PRC2在H3K27me3上的活性,FLT3-ITD与EZH2功能缺失突变在人类AML中互斥;在小鼠Flt3-ITD AML中FLT3抑制剂增加髓系成熟并减少干/祖细胞群,联合EZH1/2抑制剂可增强终末成熟并降低白血病负荷。
要点
- FLT3抑制剂经下调EZH2及PRC2活性促进FLT3-ITD白血病细胞髓系分化。
- FLT3-ITD与EZH2功能缺失突变在人类AML中互斥。
- EZH1/2抑制剂联合FLT3抑制剂增强白血病细胞终末成熟并降低白血病负荷。
核心结论
- FLT3抑制后EZH2活性降低促进FLT3-ITD白血病细胞髓系分化,为临床观察提供机制解释。
- FLT3-ITD除已知的细胞存活与增殖信号外,还通过调控PRC2活性维持髓系干/祖细胞状态。
- 研究结果支持探索EZH1/2抑制剂作为FLT3-ITD AML的治疗。
研究设计与样本
- 采用基于蛋白组学的筛选鉴定EZH2为FLT3抑制剂促分化效应的介导因子。
- 在人类AML中分析FLT3-ITD与EZH2功能缺失突变的互斥关系。
- 在小鼠Flt3-ITD AML中评估FLT3抑制剂及联合EZH1/2抑制剂对髓系成熟和白血病负荷的影响。
主要发现
- FLT3抑制剂下调EZH2蛋白表达及PRC2在H3K27me3上的活性。
- FLT3-ITD与EZH2功能缺失突变在人类AML中互斥。
- FLT3抑制剂增加小鼠Flt3-ITD AML的髓系成熟并减少干/祖细胞群。
- EZH1/2抑制剂联合FLT3抑制剂增加白血病细胞终末成熟并降低白血病负荷。
临床怎么用
- 作者认为研究结果支持探索EZH1/2抑制剂作为FLT3-ITD AML的治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Internal tandem duplication mutations in fms-like tyrosine kinase 3 (FLT3-ITD) are recurrent in acute myeloid leukemia (AML) and increase the risk of relapse. Clinical responses to FLT3 inhibitors (FLT3i) include myeloid differentiation of the FLT3-ITD clone in nearly half of patients through an unknown mechanism. We identified enhancer of zeste homolog 2 (EZH2), a component of polycomb repressive complex 2 (PRC2), as a mediator of this effect using a proteomic-based screen. FLT3i downregulated EZH2 protein expression and PRC2 activity on H3K27me3. FLT3-ITD and loss-of-function mutations in EZH2 are mutually exclusive in human AML. We demonstrated that FLT3i increase myeloid maturation with reduced stem/progenitor cell populations in murine Flt3-ITD AML. Combining EZH1/2 inhibitors with FLT3i increased terminal maturation of leukemic cells and reduced leukemic burden. Our data suggest that reduced EZH2 activity following FLT3 inhibition promotes myeloid differentiation of FLT3-ITD leukemic cells, providing a mechanistic explanation for the clinical observations. These results demonstrate that in addition to its known cell survival and proliferation signaling, FLT3-ITD has a second, previously undefined function to maintain a myeloid stem/progenitor cell state through modulation of PRC2 activity. Our findings support exploring EZH1/2 inhibitors as therapy for FLT3-ITD AML.
引用
- Sung PJ, Selvam M, Riedel SS, et al. FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia. Leukemia. 2024. PMID: 38182819. doi:10.1038/s41375-023-02131-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。